Review
(71) Total Article Views
Authors: Walford HH, Doherty TA
Published Date April 2014 Volume 2014:7 Pages 53 - 65
DOI: http://dx.doi.org/10.2147/JAA.S39119
| Received: | 06 December 2013  |
|---|---|
| Accepted: | 15 January 2014 |
| Published: | 11 April 2014 |
1Department of Medicine, 2Department of Pediatrics, University of California, La Jolla, CA, USA
Abstract: Eosinophilic asthma is now recognized as an important subphenotype of asthma based on the pattern of inflammatory cellular infiltrate in the airway. Eosinophilic asthma can be associated with increased asthma severity, atopy, late-onset disease, and steroid refractoriness. Induced sputum cell count is the gold standard for identifying eosinophilic inflammation in asthma although several noninvasive biomarkers, including fractional exhaled nitric oxide and periostin, are emerging as potential surrogates. As novel therapies and biologic agents become increasingly available, there is an increased need for specific phenotype-directed treatment strategies. Greater recognition and understanding of the unique immunopathology of this asthma phenotype has important implications for management of the disease and the potential to improve patient outcomes. The present review provides a summary of the clinical features, pathogenesis, diagnosis, and management of eosinophilic asthma.
Keywords: asthma, eosinophil, allergy, Th2, IL-4, IL-13
Post to:
CannoteaCiteulikeDel.icio.usFacebookLinkedInTwitter
No comments:
Post a Comment